Market Research Report: Genomics Ltd.
Table of Contents
1. [Company Overview](#company-overview)
2. [Products](#products)
3. [Recent Developments](#recent-developments)
Company Overview
- Name: Genomics Ltd.
- Mission: Harness the power of genomics to help people live longer, healthier lives by offering industry-leading risk identification and prevention platforms.
- Founded: 2014
- Founders: Professor Peter Donnelly, Professor Gil McVean, Dr. Gerton Lunter, and Dr. Chris Spencer.
- Key People:
- Professor Sir Peter Donnelly FRS, FMedSci - Founder & CEO
- David Thornton - President & COO
- Sneha Bakshi - Chief People Officer
- Daniel Vogel - Chief Financial Officer
- Dr. Ella Adlen - Chief of Staff
- Dr. Vincent Plagnol - Chief Scientific Officer
- Dr. Seamus Harrison - VP, Global Medical Affairs & Clinical Development
- Headquarters: King Charles House, Park End Street, Oxford, OX1 1JD, UK
- Number of Employees: Over 140, with more than 40% holding PhDs
- Revenue: No information is available.
- Known For: Genomics Ltd is renowned for its innovative application of genomics to develop precision healthcare tools, breakthroughs in drug discovery, and genomics-based approaches for preventative healthcare.
Products
Genomics Platform:
- High-level Description: An industry-leading platform leveraging a large and unique genetic database to determine individual disease risk.
- Key Features:
- Risk Identification and Prevention: Uses advanced polygenic risk scores for predicting individual disease risk.
- Genetic Data Security: Ensures personal health data is secure, not sold, and handled lawfully with consent.
- Application Across Sectors: Tailored solutions for insurers, employers, life sciences, and healthcare providers.
Precision Healthcare Tools:
- High-level Description: Tools developed for personalised health management, disease prevention and early intervention.
- Key Features:
- Personalised Risk Assessments: Utilises polygenic risk scores for major diseases.
- Stratification and Screening: Stratifies patients to tailor screening and interventions.
Drug Discovery and Development Tools:
- High-level Description: Tools and partnerships designed to integrate genomics into healthcare and drug development.
- Key Features:
- Target Discovery and Validation: Leverages genetic insights for discovering novel drug targets.
- Patient Stratification: Enhances precision medicine through detailed patient population characterisation.
Recent Developments
- New Products/Features:
- Genomics is collaborating with Bupa Health Clinics to use genetic testing in health assessments for four major diseases in the UK.
- The company has introduced PRS (Polygenic Risk Scores) to predict and stratify risk for cardiovascular diseases within NHS Health Checks.
- Partnerships:
- Continued collaboration with Vertex Pharmaceuticals, focusing on genetic tools and technologies to advance precision medicine globally.
- Leadership Changes:
- David Thornton was appointed as President, taking over internal business scaling responsibilities from Professor Gil McVean, who now serves as a non-executive Director on the board.
- Research and Innovations:
- Groundbreaking research released highlights the influence of genetics on obesity using polygenic risk scores, with published study results demonstrating the potential for a 25% reduction in preventable diseases through genetic screening.
- Newly published research indicating that 8% of the UK population is at an undetected genetic risk equivalent to carriers of familial hypercholesterolemia concerning heart disease.
- Employee Growth:
- The company's growth trajectory is supported by its expansion into new offices in Cambridge, UK, and Boston, US.
This report delivers an in-depth overview of Genomics Ltd., focusing on its comprehensive application of genomics in transforming healthcare and drug discovery, latest research developments, strategic leadership, and innovative product offerings tailored for precision medicine and preventative health solutions.
